Alira Health

Alira Health

Transaction Advisory

Business Development and Licensing

Global reach with local expertise

With offices in eight cities around the world, our team of global bankers, scientists, strategists and doctors collaborate to provide a range of development and licensing services:

  • Strong pharma and biotech expertise
  • EU-USA cross-border capabilities
  • Local coverage across the EU
  • Innovative deal structures

Why choose Alira Health?

With Alira Health as your partner, you will benefit from:

  • Access to in-house clinical, regulatory, and market access experts to capture the full value of assets
  • Experienced team with over 50 assignments to date
  • A dedicated team that can function as the business development and licensing arm for PE-owned companies

 

Related news

Events October 6, 2022
The MedTech Conference 2022
We are pleased to share that we will be joining the MedTech Conference 2022 as sponsors and speakers! This year’s edition will have more than 100 sessions focusing on today’s hot topics.
M&A MedTech Regulatory
News January 13, 2022
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. The financing was provided by key existing investors Creadev, an evergreen(...)
M&A MedTech Pharma Press Release
Articles August 3, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
Key questions to ask to help ensure that your next transaction advisory firm partnership is best positioned to achieve your goals.
M&A
News April 12, 2021
Alira Health Strengthens Growth Strategy with $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
M&A MedTech Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
M&A Pharma
News November 29, 2020
Alira Health as Strategic Advisor to Benvic in Acquisition Luc & Bel
We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.
CDMO M&A
Reports November 1, 2020
Five Key Success Factors for Managing Transactions in Full Virtual Mode
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
M&A
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.